Literature DB >> 30850915

Characterization of Cancer-Induced Nociception in a Murine Model of Breast Carcinoma.

Amanda Spring de Almeida1, Flávia Karine Rigo2, Samira Dal-Toé De Prá2, Alessandra Marcone Milioli2, Diéssica Padilha Dalenogare1, Gabriele Cheiran Pereira1, Camila Dos Santos Ritter1, Diulle Spat Peres1, Caren Tatiane de David Antoniazzi1, Carolina Stein3, Rafael Noal Moresco3, Sara Marchesan Oliveira4, Gabriela Trevisan5,6,7.   

Abstract

Severe and poorly treated pain often accompanies breast cancer. Thus, novel mechanisms involved in breast cancer-induced pain should be investigated. Then, it is necessary to characterize animal models that are reliable with the symptoms and progression of the disease as observed in humans. Explaining cancer-induced nociception in a murine model of breast carcinoma was the aim of this study. 4T1 (104) lineage cells were inoculated in the right fourth mammary fat pad of female BALB/c mice; after this, mechanical and cold allodynia, or mouse grimace scale (MGS) were observed for 30 days. To determine the presence of bone metastasis, we performed the metastatic clonogenic test and measure calcium serum levels. At 20 days after tumor induction, the antinociceptive effect of analgesics used to relieve pain in cancer patients (acetaminophen, naproxen, codeine or morphine) or a cannabinoid agonist (WIN 55,212-2) was tested. Mice inoculated with 4T1 cells developed mechanical and cold allodynia and increased MGS. Bone metastasis was confirmed using the clonogenic assay, and hypercalcemia was observed 20 days after cells inoculation. All analgesic drugs reduced the mechanical and cold allodynia, while the MGS was decreased only by the administration of naproxen, codeine, or morphine. Also, WIN 55,212-2 improved all nociceptive measures. This pain model could be a reliable form to observe the mechanisms of breast cancer-induced pain or to observe the efficacy of novel analgesic compounds.

Entities:  

Keywords:  Allodynia; Bone metastasis; Cannabinoid; NSAIDs; Opioids; WIN 55,212-2

Mesh:

Substances:

Year:  2019        PMID: 30850915     DOI: 10.1007/s10571-019-00666-8

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  75 in total

Review 1.  Molecular mechanisms of cancer pain.

Authors:  Patrick W Mantyh; Denis R Clohisy; Martin Koltzenburg; Steve P Hunt
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

2.  Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain.

Authors:  M J Schwei; P Honore; S D Rogers; J L Salak-Johnson; M P Finke; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

3.  Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Authors:  T W Vanderah; L R Gardell; S E Burgess; M Ibrahim; A Dogrul; C M Zhong; E T Zhang; T P Malan; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

4.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord.

Authors:  P Honore; N M Luger; M A Sabino; M J Schwei; S D Rogers; D B Mach; P F O'keefe; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

Review 5.  Advances in understanding bone cancer pain.

Authors:  M J Goblirsch; P Zwolak; D R Clohisy
Journal:  J Cell Biochem       Date:  2005-11-01       Impact factor: 4.429

6.  Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.

Authors:  B A Pulaski; V K Clements; M R Pipeling; S Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2000-04       Impact factor: 6.968

7.  A novel orthotopic model of breast cancer metastasis to bone.

Authors:  M Lelekakis; J M Moseley; T J Martin; D Hards; E Williams; P Ho; D Lowen; J Javni; F R Miller; J Slavin; R L Anderson
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

8.  A rat model of bone cancer pain.

Authors:  S J Medhurst; K Walker; M Bowes; B L Kidd; M Glatt; M Muller; M Hattenberger; J Vaxelaire; T O'Reilly; G Wotherspoon; J Winter; J Green; L Urban
Journal:  Pain       Date:  2002-03       Impact factor: 6.961

9.  Pharmacological characterisation of a rat model of incisional pain.

Authors:  Garth T Whiteside; James Harrison; Jamie Boulet; Lilly Mark; Michelle Pearson; Susan Gottshall; Katharine Walker
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

10.  The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci.

Authors:  Sally A DuPré; Doug Redelman; Kenneth W Hunter
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

View more
  4 in total

1.  Behavioral Battery for Testing Candidate Analgesics in Mice. I. Validation with Positive and Negative Controls.

Authors:  C M Diester; E J Santos; M J Moerke; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  2021-02-23       Impact factor: 4.030

2.  Lidocaine and bupivacaine as part of multimodal pain management in a C57BL/6J laparotomy mouse model.

Authors:  Mattea S Durst; Margarete Arras; Rupert Palme; Steven R Talbot; Paulin Jirkof
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

Review 3.  Methods Used and Application of the Mouse Grimace Scale in Biomedical Research 10 Years on: A Scoping Review.

Authors:  Alexandra L Whittaker; Yifan Liu; Timothy H Barker
Journal:  Animals (Basel)       Date:  2021-03-03       Impact factor: 2.752

4.  Nociception in a Progressive Multiple Sclerosis Model in Mice Is Dependent on Spinal TRPA1 Channel Activation.

Authors:  Camila Ritter; Diéssica Padilha Dalenogare; Amanda Spring de Almeida; Vitória Loreto Pereira; Gabriele Cheiran Pereira; Maria Fernanda Pessano Fialho; Débora Denardin Lückemeyer; Caren Tatiane Antoniazzi; Sabrina Qader Kudsi; Juliano Ferreira; Sara Marchesan Oliveira; Gabriela Trevisan
Journal:  Mol Neurobiol       Date:  2020-02-24       Impact factor: 5.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.